Current Report Filing (8-k)
June 24 2019 - 3:33PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
June 20, 2019
Date of Report (Date of earliest event reported)
AEVI
GENOMIC MEDICINE, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
1-35112
|
98-0217544
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer
Identification No.)
|
435 Devon Park Drive, Suite 715
Wayne, Pennsylvania 19087
(Address of principal executive offices,
zip code)
(610) 254-4201
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading Symbol(s)
|
Name of exchange on which registered
|
|
Common stock, par value $0.0001 per share
|
GNMX
|
Nasdaq Global Market
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
¨
|
|
Item 5.07.
|
Submission of Matters to a Vote of Security Holders.
|
On June 20, 2019, Aevi Genomic Medicine,
Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). The final results
for each of the matters submitted to a vote of stockholders at the Annual Meeting are as follows:
Proposal 1:
Election of seven directors
to hold office until the 2020 Annual Meeting of Stockholders.
|
Nominee
|
|
For
|
|
Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
Sol J. Barer
|
|
31,514,669
|
|
1,525,659
|
|
24,786
|
|
18,616,186
|
|
Eugene A. Bauer
|
|
31,478,816
|
|
1,558,812
|
|
27,486
|
|
18,616,186
|
|
Matthew D. Bayley
|
|
31,501,488
|
|
1,530,547
|
|
33,079
|
|
18,616,186
|
|
Alastair Clemow
|
|
31,516,368
|
|
1,518,527
|
|
30,219
|
|
18,616,186
|
|
Michael F. Cola
|
|
31,516,970
|
|
1,520,654
|
|
27,490
|
|
18,616,186
|
|
Barbara G. Duncan
|
|
28,236,248
|
|
4,797,825
|
|
31,041
|
|
18,616,186
|
|
Joseph J. Grano
|
|
31,493,864
|
|
1,543,764
|
|
27,486
|
|
18,616,186
|
Proposal 2:
Ratification of
the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the current fiscal
year ending December 31, 2019.
|
For
|
|
Against
|
|
Abstained
|
|
50,912,726
|
|
667,317
|
|
101,257
|
Proposal 3:
Approval, on a non-binding,
advisory basis, of the compensation of the Company’s named executive officers.
|
For
|
|
Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
31,274,263
|
|
1,703,403
|
|
87,448
|
|
18,616,186
|
Proposal 4:
Indication, on a non-binding,
advisory basis, of the preferred frequency of further executive compensation advisory votes.
|
Every 1 Year
|
|
Every 2 Years
|
|
Every 3 Years
|
|
Abstentions
|
|
Broker Non-Votes
|
|
28,101,842
|
|
225,879
|
|
4,683,758
|
|
53,635
|
|
18,616,186
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
AEVI GENOMIC MEDICINE, INC.
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Michael F. Cola
|
|
|
|
|
Name: Michael F. Cola
|
|
|
|
|
Title: President and Chief Executive Officer
|
|
Date: June 24, 2019
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aevi Genomic Medicine (NASDAQ:GNMX)
Historical Stock Chart
From Jul 2023 to Jul 2024
